Citing delays in hardware and software
installations and acceptance as well as deliveries of interventional
oncology procedures due to COVID-19, Varian (NYSE:VAR) has trimmed its fiscal Q3 revenue forecast to $800M-825M versus consensus of $873.2M.
Revenue growth for fiscal 2020 is now expected to be 7-9% compared to 9-12%.
Management will provide additional updates during
its FQ2 earnings call. It will also host a conference call today at 8:00
am ET to discuss the impact from COVID-19.
https://seekingalpha.com/news/3549632-varian-cuts-outlook-due-to-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.